TRI-MRNCT07693608
An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder
StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 18 words
- Trial status changed: Enrolling by Invitation → Active, Not Recruiting
- Secondary endpoints: details revised at 3 of 4 entries
Notable Enrolling by invitation onlyv2 Show 4 more changesShow less
- Eligibility criteria expanded, about 16 words
- Start date changed from estimate of Aug 1, 2026 to Aug 19, 2026
- Secondary endpoints revised (4)
- Site contact updated
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Effect of tirzepatide on self-reported use of stimulants
Timeframe: 32 weeks
Secondary (4)
Changes in body mass index from baseline to the end of the 20-week treatment phase
Feasibility of using tirzepatide in individuals with Stimulant Use Disorder
Changes in High-sensitivity C-reactive protein (hs-CRP) levels from baseline to the end of the 20-week treatment phase
Changes in gastrointestinal symptom severity from baseline until the end of the 20-week treatment phase
Arms and interventions
Tirzepatide ArmExperimental
Eligible participants who are enrolled will receive once-weekly subcutaneous injections of tirzepatide for a 20-week period in accordance with FDA-prescribing label guidelines.
Drugs: Tirzepatide
Sites
1 site in 1 country
- UT Southwestern Medical CenterDallas, Texas, United States